MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [10/14/2019 07:33 PDT] MYOK Expected to Trade Up After Bullish Patterns Develop
• [10/07/2019 08:03 PDT] MYOK Expected to Trade Up After Bullish Patterns Develop
• [09/27/2019 07:47 PDT] MYOK Expected to Trade Down After Bearish Patterns Develop
• [09/24/2019 07:59 PDT] MYOK Expected to Trade Up After Bullish Patterns Develop
• [09/23/2019 07:58 PDT] MYOK, Expected to Trade Lower After Bearish Insider Trading
• [09/20/2019 12:23 PDT] MyoKardia, Inc. (NASDAQ:MYOK), Up By 100.00% ($54.39) From $54.390 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [09/18/2019 07:53 PDT] MYOK Expected to Trade Up After Bullish Patterns Develop